CURE Magazine Seeks Nominations for 2019 MPN Heroes Recognition Program

The award recognizes individuals and organizations who are making a difference in the myeloproliferative neoplasm community.
BY Business Wire
PUBLISHED July 30, 2019
CURE Media Group, which reaches over 1 million patients, survivors and caregivers across an industry-leading multimedia platform devoted to cancer updates and research, is accepting nominations for the 2019 MPN Heroes® awards. This program honors organizations and individuals who have made a difference in the field of rare blood cancers known as myeloproliferative neoplasms (MPNs) by going above and beyond the standard of care, demonstrating leadership within the MPN community or a commitment to individual patients.

“We are excited to be accepting nominations for this year’s MPN Heroes Recognition Program,” said Michael J. Hennessy Jr., president of MJH Associates Inc., parent company of CURE Media Group. “We are proud to select and recognize another group of exceptional individuals who positively impact the MPN community each and every day.”

Nominations are accepted from the community at large. A panel of judges will review the nominations and pick the finalists and winners in two categories: Commitment to the Individual and Commitment to the Broader MPN Community. For more information, to submit a nomination and to learn more about this year’s rules, click here.

This year’s winners will be honored at the seventh annual MPN Heroes Celebration Event on December 6, 2019 at Sea World in Orlando, Florida.

The MPN Heroes Recognition Program is sponsored by Incyte Corporation and CURE Media Group, publishers of CURE® magazine. Incyte partners with CURE Media Group to support the program, with CURE® hosting the annual MPN Heroes Celebration Event recognizing heroes of the MPN community. Supporting the MPN community is an ongoing priority for Incyte, a global biopharmaceutical company that discovers and develops novel medicines to meet serious unmet medical needs in oncology and other diseases. Individuals or entities supported through funding or directed by Incyte are not eligible for consideration or recognition.
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In